Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

22.36USD
23 May 2016
Change (% chg)

-- (--)
Prev Close
$22.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,556,016
52-wk High
$23.01
52-wk Low
$14.18

BSX.N

Chart for BSX.N

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP),... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $30,339.54
Shares Outstanding(Mil.): 1,356.87
Dividend: --
Yield (%): --

Financials

BRIEF-Boston Scientific announces positive long-term outcomes for S-ICD system

* Boston scientific announces positive long-term outcomes for S-ICD system in the EFFORTLESS study

07 May 2016

BRIEF-Boston Scientific announces FDA approval of navigation-enabled ablation catheters

* Announces U.S. FDA approval of navigation-enabled ablation catheters Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

04 May 2016

UPDATE 3-Boston Scientific profit beats as heart stent sales rise

April 27 Boston Scientific Corp reported a better-than-expected quarterly profit, boosted by higher sales of its heart stents and clot-removal product, and the medical device maker raised its full-year revenue forecast.

27 Apr 2016

BRIEF-Boston Scientific Q1 adjusted EPS $0.28 excluding items

* Q1 earnings per share view $0.24 -- Thomson Reuters I/B/E/S

27 Apr 2016

BRIEF-Boston Scientific receives U.S. FDA approval for ImageReady MR-conditional pacing system

* Receives U.S. FDA approval for Imageready(Tm) MR-conditional pacing system

26 Apr 2016

Boston Scientific says suspends Watchman FLX sales in Europe

Boston Scientific Corp on Monday said it has temporarily stopped selling a newer version of its Watchman atrial fibrillation treatment in Europe due to a higher-than-expected rate of embolisms associated with the implant.

04 Apr 2016

Boston Scientific says suspends Watchman FLX sales in Europe

April 4 Boston Scientific Corp on Monday said it has temporarily stopped selling a newer version of its Watchman atrial fibrillation treatment in Europe due to a higher-than-expected rate of embolisms associated with the implant.

04 Apr 2016

BRIEF-Boston Scientific CEO's 2015 compensation was $11.6 mln

* CEO Michael Mahoney's 2015 total compensation was $11.6 million versus $10.5 million in 2014 - SEC Filing Source text: http://1.usa.gov/1q0NaTp Further company coverage:

23 Mar 2016

UPDATE 2-Heart device maker Boston Scientific's sales miss estimates

* Shares fall as much as 6 pct (Adds conference call details, analyst comment, background, shares)

04 Feb 2016

Boston Scientific reports 4.8 pct rise in quarterly revenue

Feb 4 Medical device maker Boston Scientific Corp reported a 4.8 percent rise in quarterly revenue, boosted by higher sales in its surgical equipment unit.

04 Feb 2016

Competitors

Earnings vs. Estimates